Ocular Therapeutix (OCUL) Earning Positive Press Coverage, Report Shows
Headlines about Ocular Therapeutix (NASDAQ:OCUL) have trended positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ocular Therapeutix earned a coverage optimism score of 0.26 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.9135060171702 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Ocular Therapeutix (NASDAQ:OCUL) traded down 1.570% during trading on Friday, hitting $5.955. 198,588 shares of the stock traded hands. Ocular Therapeutix has a one year low of $4.82 and a one year high of $11.91. The stock’s market cap is $173.03 million. The company has a 50-day moving average price of $6.28 and a 200 day moving average price of $7.98.
Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.05). Ocular Therapeutix had a negative net margin of 3,005.52% and a negative return on equity of 101.03%. The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.51 million. During the same quarter last year, the business posted ($0.46) earnings per share. The business’s quarterly revenue was up .0% compared to the same quarter last year. Analysts expect that Ocular Therapeutix will post ($2.29) earnings per share for the current year.
A number of research analysts have recently commented on OCUL shares. Morgan Stanley cut shares of Ocular Therapeutix from an “overweight” rating to an “equal weight” rating and set a $16.00 target price on the stock. in a research report on Friday, June 23rd. Cantor Fitzgerald set a $35.00 price target on shares of Ocular Therapeutix and gave the stock a “buy” rating in a research note on Monday, July 10th. BTIG Research restated a “neutral” rating on shares of Ocular Therapeutix in a research note on Monday, July 17th. ValuEngine upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Finally, HC Wainwright assumed coverage on shares of Ocular Therapeutix in a research report on Wednesday, July 26th. They set a “buy” rating and a $10.00 price target for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $24.00.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.
Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.